Pre-eclampsia. Pre-eclampsia
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive metformin 500 mg oral tablets of Exir pharmaceutical company once a day until the end of pregnancy. Intervention 2: Control grou
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 50 Years
Inclusion criteria
Inclusion criteria: Pregnant mothers with low pregnancy-related plasma protein A referred to kousar Clinic Normal arterial Doppler ultrasound Age 18-50 years Consent to participate in the study
Exclusion criteria
Exclusion criteria: History of intrauterine growth restriction or preeclampsia, gestational hypertension or pregnancy complications in previous pregnancies History of congenital disease History of liver or kidney failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional liver enzymes. Timepoint: in the 14th, 28th, 32nd weeks of pregnancy and at the time of delivery. Method of measurement: laboratory test.;Systolic and diastolic blood pressure. Timepoint: in the 14th, 28th, 32nd weeks of pregnancy and at the time of delivery. Method of measurement: Mercury sphygmomanometer.;Proteinuria. Timepoint: in the 14th, 28th, 32nd weeks of pregnancy and at the time of delivery. Method of measurement: Urinalysis test.;Preterm delivery. Timepoint: Delivery between 20 and 37 weeks. Method of measurement: Delivery.;Low birth weight. Timepoint: Birth weight less than 2500 grams. Method of measurement: scales.;Type of delivery. Timepoint: How the baby is born. Method of measurement: Cesarean-vaginal. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Maryam Maktabi
Arak University of Medical Sciences
Outcome results
None listed